Please use this identifier to cite or link to this item:
Type: Journal article
Title: 1D09C3, an mAb specific for MHC-II
Author: Zola, H.
Beare, A.
Citation: Current Opinion in Molecular Therapeutics, 2008; 10(1):68-74
Publisher: Pharmapress Ltd
Issue Date: 2008
ISSN: 1464-8431
Statement of
H Zola and A Beare
Abstract: GPC Biotech AG is developing 1D09C3, an anti-MHC class II (HLA-DR) fully human IgG4 antibody isolated by MorphoSys AG (from its HuCAL library of human antibodies), for the potential treatment of hematological malignancies. In December 2006, positive safety data from two phase I clinical trials were reported. Final phase I data were expected in mid-2007; however, no additional data have been released at the time of publication.
Keywords: Animals; Humans; Antibodies, Monoclonal; Histocompatibility Antigens Class II; Drug Evaluation, Preclinical; Antibody Specificity; Structure-Activity Relationship; Clinical Trials as Topic; Patents as Topic; Antibodies, Monoclonal, Humanized; Contraindications
RMID: 0020080093
Description (link):
Appears in Collections:Paediatrics publications

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.